SCHEMBL3392230

SCHEMBL3392230

O=P(O)(O)N1CCN(P(=O)(O)O)CCN(P(=O)(O)O)CCN(P(=O)(O)O)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 3/20 0.33
MMP1 P03956 2/20 0.33
MMP3 P08254 2/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MAPT P10636 1/20 0.33
ABCB11 O95342 1/20 0.33
LMNA P02545 1/20 0.33
CHRM2 P08172 1/20 0.33
CYP3A4 P08684 1/20 0.33
ADRA2A P08913 1/20 0.33
CHRM1 P11229 1/20 0.33
DRD2 P14416 1/20 0.33
HPGD P15428 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
CHRM3 P20309 1/20 0.33
CYP2B6 P20813 1/20 0.33
SLC6A2 P23975 1/20 0.33
HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15536892 1.00 FDPS (0.33) FDPSMMP1MMP3MMP2MMP9
SCHEMBL654555 1.00
SCHEMBL237224 0.86
SCHEMBL8028936 0.83 MAPT (0.46) FDPSMMP1MMP3MMP2MMP9
SCHEMBL2235976 0.83 MAPT (0.46) FDPSMMP1MMP3MMP2MMP9
SCHEMBL28736797 0.83 MAPT (0.46) FDPSMMP1MMP3MMP2MMP9
Bromide SCHEMBL28820215 0.81 MAPT (0.44) FDPSMMP1MMP3MMP2MMP9
SCHEMBL21169593 0.79
SCHEMBL96867 0.78 CA2 (0.37) CA2
SCHEMBL2974382 0.78 MMP1 (0.50) MMP1MMP3MAPTSMN1; SMN2MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024213785-A1 PROTEIN-BASED BIOSENSOR SUITABLE FOR MRI IMAGING FUNDACIÓN PÚBLICA GALEGA INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA (ES) 2024-10-17 WO claimed
EP-3642299-A1 COMPOSITIONS AND METHODS FOR CONTROLLING STRONG ACID SYSTEMS Saudi Arabian Oil Company (SA) 2020-04-29 EP claimed
US-20190010385-A1 COMPOSITIONS AND METHODS FOR CONTROLLING STRONG ACID SYSTEMS ARAMCO SERVICES COMPANY 2019-01-10 US claimed
WO-2018237237-A1 COMPOSITIONS AND METHODS FOR CONTROLLING STRONG ACID SYSTEMS SAUDI ARABIAN OIL COMPANY (SA) 2018-12-27 WO claimed
US-9701895-B2 Dual purpose viscosifier-scale inhibitors for use in subterranean formation operations HALLIBURTON ENERGY SERVICES, INC. (US) 2017-07-11 US claimed
US-20160168456-A1 DUAL PURPOSE VISCOSIFIER-SCALE INHIBITORS FOR USE IN SUBTERRANEAN FORMATION OPERATIONS HALLIBURTON ENERGY SERVICES, INC. (US) 2016-06-16 US claimed
WO-2015076820-A1 DUAL PURPOSE VISCOSIFIER-SCALE INHIBITORS FOR USE IN SUBTERRANEAN FORMATION OPERATIONS HALLIBURTON ENERGY SERVICES, INC. (US) 2015-05-28 WO claimed
WO-2024213785-A1 PROTEIN-BASED BIOSENSOR SUITABLE FOR MRI IMAGING FUNDACIÓN PÚBLICA GALEGA INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA (ES) 2024-10-17 WO disclosed
CN-118695878-A Radioactive complexes and radiopharmaceuticals of anti-VEGF antibodies 日本医事物理股份有限公司 2024-09-24 CN disclosed
CN-118159305-A Radioactive complexes and radiopharmaceuticals of deglycosylated antibodies 日本医事物理股份有限公司 2024-06-07 CN disclosed
US-11912937-B2 Acidizing treatment fluid for delayed acidification in the oil field industry NOURYON CHEMICALS INTERNATIONAL B.V. (NL) 2024-02-27 US disclosed
US-11891570-B2 Salt of monochloroacetic acid with acid for delayed acidification in the oil field industry NOURYON CHEMICALS INTERNATIONAL B.V. (NL) 2024-02-06 US disclosed
US-11702465-B1 Synthetic anti-plague antibodies TRIAD NATIONAL SECURITY, LLC (US) 2023-07-18 US disclosed
US-20190010385-A1 COMPOSITIONS AND METHODS FOR CONTROLLING STRONG ACID SYSTEMS ARAMCO SERVICES COMPANY 2019-01-10 US disclosed
WO-2018237237-A1 COMPOSITIONS AND METHODS FOR CONTROLLING STRONG ACID SYSTEMS SAUDI ARABIAN OIL COMPANY (SA) 2018-12-27 WO disclosed
US-9701895-B2 Dual purpose viscosifier-scale inhibitors for use in subterranean formation operations HALLIBURTON ENERGY SERVICES, INC. (US) 2017-07-11 US disclosed
US-20160168456-A1 DUAL PURPOSE VISCOSIFIER-SCALE INHIBITORS FOR USE IN SUBTERRANEAN FORMATION OPERATIONS HALLIBURTON ENERGY SERVICES, INC. (US) 2016-06-16 US disclosed
WO-2015076820-A1 DUAL PURPOSE VISCOSIFIER-SCALE INHIBITORS FOR USE IN SUBTERRANEAN FORMATION OPERATIONS HALLIBURTON ENERGY SERVICES, INC. (US) 2015-05-28 WO disclosed
EP-1793868-B1 LIPOSOMAL CONTRAST AGENTS FOR CEST IMAGING GUERBET SA (FR) 2010-12-29 EP disclosed
US-20070292354-A1 Contrast Agents Encapsulating Systems for Cest Imaging GUERBET (FR) 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070292354-A1 Contrast Agents Encapsulating Systems for Cest Imaging SLC46A1, CEPT1, MPST FDPS 1517/4885MMP1 1912/4885MMP3 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.